Phase 2 study of add-on parsaclisib for patients with myelofibrosis and suboptimal response to ruxolitinib: final results

Authors :: Yacoub, Abdulraheem
Borate, Uma
Rampal, Raajit K.
Ali, Haris
Wang, Eunice S.
Gerds, Aaron T.
Hobbs, Gabriela
Kremyanskaya, Marina
Winton, Elliott
O’Connell, Casey
Goel, Swati
Oh, Stephen T.
Schiller, Gary
McCloskey, James
Palmer, Jeanne
Holmes, Houston
Hager, Steven
Assad, Albert
Erickson-Viitanen, Susan
Zhou, Feng
Daver, Naval
Source :: Blood Advances; 20240101, Issue: Preprints
Publication Year :: 2024
Abstract: •Parsaclisib, a PI3Kδ inhibitor, reduced spleen volume and improved symptom scores when added to ruxolitinib for patients with myelofibrosis.•The safety and tolerability of the combination was acceptable, and daily parsaclisib dosing may provide the greatest benefit.

Full Text Access

Tools